Peripheral chemokine levels in women with recurrent major depression with suicidal ideation;Níveis periféricos de quimiocina em mulheres com depressão maior com ideaç̃o suicida

Revista Brasileira de Psiquiatria

Volumn 34, Issue 1, 2012, Pages 71-75

  Grassi Oliveira, Rodrigo ^a   Brieztke, Elisa ^b   Teixeira, Antônio ^c   Pezzi, Júlio Carlos ^d   Zanini, Márcio ^b   Lopes, Rodrigo Pestana ^a   Bauer, Moisés Evandro ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; EOTAXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR DEPRESSION; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SUICIDAL IDEATION;

EID: 84858065556     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462012000100013     Document Type: Article

References (32)

1. (WHO) WHO. Suicide prevention (SUPRE). 2011 [cited 2011 27/06/2011]; Available on: http://www.who.int/mental_health/prevention/suicide/suicideprevent/en/.
2. Mann JJ, Currier DM. Stress, genetics and epigenetic effects on the neurobiology of suicidal behavior and depression. Eur Psychiatry. 2010; 25(5):268-71.
3. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009; 65(9):732-41.
4. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009; 71(2):171-86.
5. Grassi-Oliveira R, Brietzke E, Pezzi JC, Lopes RP, Teixeira AL, Bauer ME. Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder. Psychiatry Clin Neurosci. 2009; 63(2):202-8.
6. Brietzke E, Stabellini R, Grassi-Oliveira R, Lafer B. Cytokines in Bipolar Disorder: Recent Findings, Deleterious Effects But Promise for Future Therapeutics. CNS Spectrums. 2011; 16(7):579-90.
7. Takahashi K, Funata N, Ikuta F, Sato S. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J Neuroinflammation. 2008; 5:11.
8. Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti- inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics. 2010; 7(1):22-30.
9. Banisadr G, Rostene W, Kitabgi P, Parsadaniantz SM. Chemokines and brain functions. Curr Drug Targets Inflamm Allergy. 2005; 4(3):387-99.
10. Moreira MA, Souza AL, Lana-Peixoto MA, Teixeira MM, Teixeira AL. Chemokines in the cerebrospinal fluid of patients with active and stable relapsing-remitting multiple sclerosis. Braz J Med Biol Res. 2006; 39(4):441-5.
11. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YA, Bresolin N, Scarpini E. Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2006; 66(1):146-7.
12. Kim TS, Lim HK, Lee JY, Kim DJ, Park S, Lee C, Lee CU. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2008; 436(2):196-200.
13. Drexhage RC, Padmos RC, de Wit H, Versnel MA, Hooijkaas H, van der Lely AJ, van Beveren N, deRijk RH, Cohen D. Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients? Schizophr Res. 2008; 102(1-3):352-5.
14. Teixeira AL, Reis HJ, Nicolato R, Brito-Melo G, Correa H, Teixeira MM, Romano-Silva MA. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(3):710-4.
15. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun. 2009; 23(8):1079-82.
16. Rostene W, Kitabgi P, Parsadaniantz SM. Chemokines: a new class of neuromodulator? Nat Rev Neurosci. 2007; 8(11):895-903.
17. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354(6):610-21.
18. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol. 1997; 15:675-705.
19. Limatola C, Lauro C, Catalano M, Ciotti MT, Bertollini C, Di Angelantonio S, Ragozzino D, Eusebi F. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol. 2005; 166(1-2):19-28.
20. Ragozzino D, Di Angelantonio S, Trettel F, Bertollini C, Maggi L, Gross C, Charo IF, Limatola C, Eusebi F. Chemokine fractalkine/ CX3CL1 negatively modulates active glutamatergic synapses in rat hippocampal neurons. J Neurosci. 2006; 26(41):10488-98.
21. Jedynak M, Siemiatkowski A, Gacko M, Mroczko B, Borkowski J. Serum concentrations of MCP-1 and RANTES in patients during aortic surgery: the relationship with ischemia-reperfusion. Arch Immunol Ther Exp (Warsz). 2004; 52(3):201-7.
22. Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun. 2011; 25(2):335-9.
23. Lehto SM, Niskanen L, Herzig KH, Tolmunen T, Huotari A, Viinamaki H, Koivumaa-Honkanen H, Honkalampi K, Ruotsalainen H, Hintikka J. Serum chemokine levels in major depressive disorder. Psychoneuroendocrinology. 2010; 35(2):226-32.
24. Hollingshead AB. Four factor index of social status. New Haven, CT: Yale University Department of Sociology; 1975.
25. Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, Sinacore J, Devane CL. Pro-inflammatory biomakers in depression: Treatment with venlafaxine. World J Biol Psychiatry. 2009; 10:313-23.
26. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008; 42(2):151-7.
27. Mendlovic S, Mozes E, Eilat E, Doron A, Lereya J, Zakuth V, Spirer Z. Immune activation in non-treated suicidal major depression. Immunol Lett. 1999; 67(2):105-8.
28. Kim YK, Lee SW, Kim SH, Shim SH, Han SW, Choi SH, Lee BH. Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(2):356-61.
29. Kalehua AN, Nagel JE, Whelchel LM, Gides JJ, Pyle RS, Smith RJ, Kusiakr JW, Taub DD. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. Exp Cell Res. 2004; 297(1):197-211.
30. Zisman DA, Kunkel SL, Strieter RM, Tsai WC, Bucknell K, Wilkowski J, Standiford TJ. MCP-1 protects mice in lethal endotoxemia. J Clin Invest. 1997; 99(12):2832-6.
31. Blanco I, Janciauskiene S, Nita I, Fernandez-Bustillo E, Carcaba V, Gallo C, Alvarez-Rico M, de Serres F, Béridze N. Low plasma levels of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNFalpha), and vascular endothelial growth factor (VEGF) in patients with alpha1-antitrypsin deficiency-related fibromyalgia. Clin Rheumatol. 2010; 29(2):189-97.
32. Lindqvist D, Janelidze S, Erhardt S, Traskman-Bendz L, Engstrom G, Brundin L. CSF biomarkers in suicide attempters - a principal component analysis. Acta Psychiatr Scand. 2011; 124(1):52-61.